Page 212 - Read Online

Page 708 Alonso-Peña et al. Cancer Drug Resist 2019;2:680-709 I http://dx.doi.org/10.20517/cdr.2019.006

168. Galmarini CM, Bouchet BP, Audoynaud C, Lamblot C, Falette N, et al. A p21/WAF1 mutation favors the appearance of drug resistance
to paclitaxel in human noncancerous epithelial mammary cells. Int J Cancer 2006;119:60-6.
169. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009;124:511-5.
170. Li M, Wu XM, Gao J, Yang F, Zhang CL, et al. Mutations in the P10 region of procaspase-8 lead to chemotherapy resistance in acute
myeloid leukemia by impairing procaspase-8 dimerization. Cell Death Dis 2018;9:516.
171. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med
Oncol 2010;27:255-61.
172. Tanaka Y, Kanai F, Tada M, Asaoka Y, Guleng B, et al. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese
patients. Oncogene 2006;25:2950-2.
173. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular
carcinomas. Oncogene 2005;24:1477-80.
174. Kudo Y, Tanaka Y, Tateishi K, Yamamoto K, Yamamoto S, et al. Altered composition of fatty acids exacerbates hepatotumorigenesis
during activation of the phosphatidylinositol 3-kinase pathway. J Hepatol 2011;55:1400-8.
175. Dogruluk T, Tsang YH, Espitia M, Chen F, Chen T, et al. Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping
of Rare Mutations. Cancer Res 2015;75:5341-54.
176. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates
acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2011;337:155-61.
177. Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, et al. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol
Res 2007;37:389-96.
178. Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol 2011;7:1149-67.
179. Huynh H, Hao HX, Chan SL, Chen D, Ong R, et al. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular
Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Mol Cancer Ther 2015;14:1224-35.
180. Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, et al. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular
carcinoma through SHP-1-mediated inhibition of STAT3. Mol Cancer Ther 2012;11:452-63.
181. Yang S, Luo C, Gu Q, Xu Q, Wang G, et al. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in
hepatocellular carcinoma. Oncotarget 2016;7:5461-9.
182. Rao CV, Asch AS, Yamada HY. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer.
Carcinogenesis 2017;38:2-11.
183. Ou DL, Lee BS, Chang YC, Lin LI, Liou JY, et al. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma
by inhibiting the insulin-like growth factor pathway. PLoS One 2013;8:e66589.
184. Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, et al. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib
resistance in hepatocellular carcinoma. Gut 2017;66:530-40.
185. Lee YI, Han YJ, Lee SY, Park SK, Park YJ, et al. Activation of insulin-like growth factor II signaling by mutant type p53: physiological
implications for potentiation of IGF-II signaling by p53 mutant 249. Mol Cell Endocrinol 2003;203:51-63.
186. Huang WC, Tsai CC, Chan CC. Mutation analysis and copy number changes of KRAS and BRAF genes in Taiwanese cases of biliary
tract cholangiocarcinoma. J Formos Med Assoc 2017;116:464-8.
187. Xu RF, Sun JP, Zhang SR, Zhu GS, Li LB, et al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese
cholangiocarcinoma patients. Biomed Pharmacother 2011;65:22-6.
188. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, et al. The Ras-RasGAP complex: structural basis for GTPase
activation and its loss in oncogenic Ras mutants. Science 1997;277:333-8.
189. Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary
tract cancers: a population-based study in China. Clin Cancer Res 2002;8:3156-63.
190. Yin PH, Wu CC, Lin JC, Chi CW, Wei YH, et al. Somatic mutations of mitochondrial genome in hepatocellular carcinoma. Mitochondrion
2010;10:174-82.
191. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
192. Sui X, Chen R, Wang Z, Huang Z, Kong N, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer
treatment. Cell Death Dis 2013;4:e838.
193. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
194. Leyva-Illades D, McMillin M, Quinn M, Demorrow S. Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment. Transl
Gastrointest Cancer 2012;1:71-80.
195. Yamada S, Okumura N, Wei L, Fuchs BC, Fujii T, et al. Epithelial to mesenchymal transition is associated with shorter disease-free
survival in hepatocellular carcinoma. Ann Surg Oncol 2014;21:3882-90.
196. Giannelli G, Koudelkova P, Dituri F, Mikulits W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol
2016;65:798-808.
197. Kong P, Christia P, Saxena A, Su Y, Frangogiannis NG. Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and
fibrosis. Am J Physiol Heart Circ Physiol 2013;305:H1363-72.
198. Kremmer E, Thierfelder S, Kummer U, Lederer R, Mysliwietz J. Neutralization of immunosuppression by antibodies against variable
as well as constant regions of monoclonal anti-Thy-1 xenoantibodies and their ability to be suppressed by initial T cell depletion.
Transplantation 1989;47:641-6.
199. Vaquero J, Guedj N, Claperon A, Nguyen Ho-Bouldoires TH, Paradis V, et al. Epithelial-mesenchymal transition in cholangiocarcinoma: